Peritoneal carcinomatosis of gastrointestinal tumors: Where are we now?

Table 1 Results of large studies on cytoreductive surgery and intraperitoneal chemotherapy in peritoneal carcinomatosis from colorectal origin

Ref.	Study design	Number of patients	Complete CRS	Intraperitoneal chemotherapy	Median follow-up (mo)	Median survival (mo)
Verwaal et al[12]	Randomized	105	NA	HIPEC	21.6	22.3
Glehen et al[47]	Retrospective	506	53.5%	HIPEC/EPIC	53.0	19.2
Levine et al[46]	Retrospective	133	NA	HIPEC	55.4	16.4
Elias et al[9]	Retrospective	48	NA	HIPEC	63.0	62.7
Elias et al[42]	Retrospective	523	84%	HIPEC/EPIC	45.0	30.1

CRS: Cytoreductive surgery; NA: Not available; HIPEC: Hyperthermic intraperitoneal chemotherapy; EPIC: Early postoperative intraperitoneal chemotherapy.